Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease

Ann Neurol. 2003:53 Suppl 3:S149-57; discussion S157-9. doi: 10.1002/ana.10514.
No abstract available

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Humans
  • Neuroprotective Agents / adverse effects
  • Neuroprotective Agents / classification
  • Neuroprotective Agents / therapeutic use*
  • Parkinson Disease / drug therapy*

Substances

  • Neuroprotective Agents